Bioequivalence and in-vivo studies MCQs With Answer

Bioequivalence and in-vivo studies MCQs With Answer

Bioequivalence (BE) and in-vivo studies lie at the heart of regulatory approval pathways for generic and certain complex drug products. For M. Pharm students specializing in Regulatory Affairs, mastering BE concepts—study design, pharmacokinetic endpoints, statistics, bioanalytical validation, and ethical safeguards—is crucial for real-world dossier development. This set of MCQs focuses on the science and regulation underpinning BE, including crossover and replicate designs, handling highly variable and narrow therapeutic index drugs, BCS-based biowaivers, dissolution criteria, and bioanalytical quality. You will also revisit key PK metrics, TOST procedures, food-effect study requirements, and documentation practices aligned with global expectations (FDA/EMA/WHO/CDSCO). Use these questions to assess your readiness for both exams and industry practice.

Q1. In a standard average bioequivalence assessment for an immediate-release oral product, the primary statistical criterion is:

• Geometric mean ratios for AUC and Cmax exactly equal to 100%
• 90% confidence intervals for log-transformed AUC and Cmax within 80.00% to 125.00%
• 95% confidence intervals for untransformed AUC and Cmax within 80.00% to 120.00%
• Non-inferiority margin of 10% on untransformed AUC only

Correct Answer: 90% confidence intervals for log-transformed AUC and Cmax within 80.00% to 125.00%

Q2. Why are pharmacokinetic parameters such as AUC and Cmax typically log-transformed before statistical analysis in BE studies?

• To increase the arithmetic mean of the parameters
• To stabilize variance and allow ratio-based inference using normal-theory methods
• To convert skewed data to a Poisson distribution
• To remove period and sequence effects entirely

Correct Answer: To stabilize variance and allow ratio-based inference using normal-theory methods

Q3. Which study design is most appropriate for highly variable drugs to enable reference-scaled average bioequivalence?

• Parallel-group two-arm design
• Two-period, two-sequence crossover without replication
• Replicate crossover design (e.g., TRTR/RTRT or TRR/RTR/RRT) to estimate within-subject variability of the reference
• Single-dose, single-period open-label study

Correct Answer: Replicate crossover design (e.g., TRTR/RTRT or TRR/RTR/RRT) to estimate within-subject variability of the reference

Q4. The minimum recommended washout between periods in a crossover BE study is generally:

• At least 2 elimination half-lives of the drug
• At least 3 elimination half-lives of the drug
• At least 5 elimination half-lives of the drug
• At least 24 hours irrespective of the drug’s half-life

Correct Answer: At least 5 elimination half-lives of the drug

Q5. In the ANOVA model for a standard 2×2 crossover BE study, which effects are typically included?

• Treatment, period, sequence as fixed effects; subject nested within sequence as a random effect
• Treatment only as a fixed effect; subject as a random effect
• Sequence only as a random effect; all else ignored
• Period and treatment as random effects; subject as a fixed effect

Correct Answer: Treatment, period, sequence as fixed effects; subject nested within sequence as a random effect

Q6. For immediate-release oral products, the usual primary PK endpoints for BE are:

• AUC0–t, AUC0–∞, and Cmax
• Tmax and t1/2 only
• Cmin and fluctuation index
• Mean residence time and clearance

Correct Answer: AUC0–t, AUC0–∞, and Cmax

Q7. Regarding fed-state bioequivalence studies for immediate-release products, which statement is most accurate?

• They are never required if fasting studies pass BE
• They are conducted under a standardized high-fat, high-calorie meal when the reference product label indicates food intake affects absorption
• They must use a low-fat meal to avoid food effects
• They are required only for narrow therapeutic index drugs

Correct Answer: They are conducted under a standardized high-fat, high-calorie meal when the reference product label indicates food intake affects absorption

Q8. A BCS-based biowaiver is most commonly applicable to which scenario for immediate-release solid oral dosage forms?

• BCS Class II drugs with slow dissolution and novel excipients
• BCS Class I (and in some jurisdictions Class III) drugs with rapid/very rapid dissolution and excipients not affecting GI transit or permeability
• BCS Class IV drugs with variable bioavailability
• Any modified-release product with high solubility

Correct Answer: BCS Class I (and in some jurisdictions Class III) drugs with rapid/very rapid dissolution and excipients not affecting GI transit or permeability

Q9. The key determinant for sample size in a BE study is:

• The number of available bioanalytical runs
• Within-subject coefficient of variation and the desired power to keep the 90% CI within acceptance limits
• Total number of formulations evaluated in preformulation
• Half-life of the drug only

Correct Answer: Within-subject coefficient of variation and the desired power to keep the 90% CI within acceptance limits

Q10. For narrow therapeutic index (NTI) drugs, regulators may require:

• No change to BE limits; always 80–125% for all metrics
• Wider BE limits for Cmax to 70–143%
• Tighter BE limits around 90.00–111.11% for exposure metrics, reflecting reduced allowable variability
• Only pharmacodynamic endpoint comparisons

Correct Answer: Tighter BE limits around 90.00–111.11% for exposure metrics, reflecting reduced allowable variability

Q11. The primary purpose of incurred sample reanalysis (ISR) in BE studies is to:

• Recalculate AUC0–∞ using compartmental modeling
• Verify reproducibility of the bioanalytical method in actual study samples
• Replace outlier concentrations with model-predicted values
• Reduce the number of calibration standards required

Correct Answer: Verify reproducibility of the bioanalytical method in actual study samples

Q12. Which statement about Tmax in BE studies is most appropriate?

• Tmax is a primary endpoint and always subject to equivalence testing
• Tmax is typically analyzed using nonparametric methods and is a secondary/supportive endpoint
• Tmax must be identical between formulations
• Tmax is ignored in all submissions

Correct Answer: Tmax is typically analyzed using nonparametric methods and is a secondary/supportive endpoint

Q13. Many regulatory authorities require at least how many evaluable subjects in a standard crossover BE study?

• 6
• 8
• 12
• 30

Correct Answer: 12

Q14. Under which circumstances is a steady-state BE study preferred over a single-dose study?

• For drugs with extremely short half-life and no accumulation
• For modified-release products or drugs where single-dose data do not reflect steady-state exposure
• For all BCS Class I drugs
• When the reference product is unavailable

Correct Answer: For modified-release products or drugs where single-dose data do not reflect steady-state exposure

Q15. Regarding dissolution comparison for biowaivers and strength waivers, which criterion indicates similarity?

• f2 similarity factor between 50 and 100 across relevant pH media
• f1 difference factor greater than 15
• f2 less than 30 indicates rapid dissolution
• No dissolution testing is required if BE is demonstrated in vivo

Correct Answer: f2 similarity factor between 50 and 100 across relevant pH media

Q16. Which ethical requirement is mandatory for in-vivo BE studies in human volunteers?

• Only sponsor’s internal approval
• Institutional Ethics Committee/IRB approval, written informed consent, and compliance with GCP
• Anonymous enrollment without consent to avoid bias
• Consent from the analytical laboratory head

Correct Answer: Institutional Ethics Committee/IRB approval, written informed consent, and compliance with GCP

Q17. According to bioanalytical method validation standards for small molecules, acceptable accuracy and precision criteria are typically:

• ±5% at all concentrations
• ±10% at LLOQ and ±5% at other levels
• ±20% at LLOQ and ±15% at other quality control levels
• ±25% at all concentrations

Correct Answer: ±20% at LLOQ and ±15% at other quality control levels

Q18. Which is an acceptable, pre-specified reason to exclude a subject’s PK profile from BE analysis?

• Failure to meet the 80–125% BE limits
• Emesis occurring within twice the median Tmax in a fasting study, compromising absorption
• Outlier concentrations without any documented cause
• Low Cmax compared to expected literature values

Correct Answer: Emesis occurring within twice the median Tmax in a fasting study, compromising absorption

Q19. Which approach is currently used by regulators for generic BE decisions?

• Individual bioequivalence focusing on subject-by-formulation interaction
• Population bioequivalence emphasizing variance components only
• Average bioequivalence based on geometric mean ratios and 90% CIs
• Clinical endpoint equivalence trials only

Correct Answer: Average bioequivalence based on geometric mean ratios and 90% CIs

Q20. For locally acting topical dermatological products (e.g., creams/ointments), the BE approach commonly relies on:

• Systemic PK BE alone, since plasma levels always reflect local efficacy
• Clinical endpoint trials only, without any in vitro testing
• Comparative in vitro approaches (e.g., IVRT/IVPT) and Q1/Q2/Q3 sameness, as per product-specific guidance
• Urinary excretion BE because the drug is mostly topical

Correct Answer: Comparative in vitro approaches (e.g., IVRT/IVPT) and Q1/Q2/Q3 sameness, as per product-specific guidance

Download